Article Text

Download PDFPDF

  1. L. Robles Kirkegard1,
  2. E. Rubio Romero1,
  3. P. León1
  1. 1Servicio Andaluz Salud, Hospital Universitario Virgen del Roció, Sevilla, Spain


Background Upadacitinib is a JAK inhibitor recently approved for rheumatoid arthritis treatment with promising results in its studies for severe moderate RA for which conventional therapies failed.

Objectives To study and describe the evolution of patients diagnosed with RA and treated with Upadacitinib who had inadequate response to biological therapy in association or not with DMARDs and GC for 6 months.

Methods A population of 23 patients (19 of them female) with RA on treatment with Upadacitinib was analyzed over 6 months. Using patient-reported outcomes (PROs) to measure disease activity by visual analogue scale (VAS), the HAQ Disability Index (HAQ-DI), Disease Activity Score (DAS28), and morning stiffness duration. The age´s (average ± SD) = 53 ± 10 years and time of disease evolution (average ± SD) = 17.6 ± 23.3 years. Pretreatment HAQ (average ± SD) = 2.2 ± 0.5. All patients received previous biologic treatments and 61% (14 patients) combined therapy with DMARDs. Only 2 cases had no glucocorticoid treatment prior to treatment with Upadacitinib.

Results In 3 months’ time, most patients (81%, n = 21) treated with Upadacitinib were able to reduce GC dose, and this reduction was maintained 6 months from the beginning of the treatment. After 3 months of treatment, most patients experienced an enhancement in DAS28 (89%, n = 18), with an average improvement in DAS28 of (± SD) 1.87±1.09 units. Regarding the pain (VAS), 67% of the patients showed improvement after 3 months (n=18), reaching 71% after 6 months (n=17). Sixty-eight percent of treated patients showed a reduction in morning stiffness after 3 months (n = 19), and this improvement increased up to 84% of treated patients at 6 months (n = 19). Side effects were observed in five patients, consisting of dizziness and nausea. In no case were they a reason for the withdrawal of the drug. Treatment was withdrawn in three patients due to primary failure.

Conclusion Treatment with Upadacitinib allows GS dose reduction, as well as an improvement in DAS28, VAS and morning stiffness at three months and six of treatment. These data are in line with the evidence published in Upadacitinib pivotal studies, meaning a good alternative in the treatment of patients with moderate or severe RA.

References [1]Strand V et al. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology (Oxford). 2021 Dec 1;60(12):5583-5594. doi: 10.1093/rheumatology/keab158. PMID: 33590829; PMCID: PMC8645276.

[2]Nash P. Clinical use of Jak 1 inhibitors for rheumatoid arthritis. Rheumatology (Oxford). 2021 May 5;60(Suppl 2):ii31-ii38. doi: 10.1093/rheumatology/keab265. PMID: 33950231; PMCID: PMC8098107.

[3]Avci AB, Feist E, Burmester GR. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2021 May 5;60(Suppl 2):ii11-ii16. doi: 10.1093/rheumatology/keaa893. PMID: 33950228; PMCID: PMC8098113

Disclosure of Interests None declared.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.